Literature DB >> 30404798

Reactivation of Simian Varicella Virus in Rhesus Macaques after CD4 T Cell Depletion.

Vicki Traina-Dorge1, Brent E Palmer2, Colin Coleman3, Meredith Hunter1, Amy Frieman3, Anah Gilmore3, Karen Altrock3, Lara Doyle-Meyers4, Maria A Nagel3,5, Ravi Mahalingam6.   

Abstract

Rhesus macaques intrabronchially inoculated with simian varicella virus (SVV), the counterpart of human varicella-zoster virus (VZV), developed primary infection with viremia and rash, which resolved upon clearance of viremia, followed by the establishment of latency. To assess the role of CD4 T cell immunity in reactivation, monkeys were treated with a single 50-mg/kg dose of a humanized monoclonal anti-CD4 antibody; within 1 week, circulating CD4 T cells were reduced from 40 to 60% to 5 to 30% of the total T cell population and remained low for 2 months. Very low viremia was seen only in some of the treated monkeys. Zoster rash developed after 7 days in the monkey with the most extensive CD4 T cell depletion (5%) and in all other monkeys at 10 to 49 days posttreatment, with recurrent zoster in one treated monkey. SVV DNA was detected in the lung from two of five monkeys, in bronchial lymph nodes from one of the five monkeys, and in ganglia from at least two dermatomes in three of five monkeys. Immunofluorescence analysis of skin rash, lungs, lymph nodes, and ganglia revealed SVV ORF63 protein at the following sites: sweat glands in skin; type II cells in lung alveoli, macrophages, and dendritic cells in lymph nodes; and the neuronal cytoplasm of ganglia. Detection of SVV antigen in multiple tissues upon CD4 T cell depletion and virus reactivation suggests a critical role for CD4 T cell immunity in controlling varicella virus latency.IMPORTANCE Reactivation of latent VZV in humans can result in serious neurological complications. VZV-specific cell-mediated immunity is critical for the maintenance of latency. Similar to VZV in humans, SVV causes varicella in monkeys, establishes latency in ganglia, and reactivates to produce shingles. Here, we show that depletion of CD4 T cells in rhesus macaques results in SVV reactivation, with virus antigens found in zoster rash and SVV DNA and antigens found in lungs, lymph nodes, and ganglia. These results suggest the critical role of CD4 T cell immunity in controlling varicella virus latency.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  CD4 T cell depletion; animal model; simian varicella virus reactivation

Mesh:

Year:  2019        PMID: 30404798      PMCID: PMC6340024          DOI: 10.1128/JVI.01375-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Disseminated varicella infection in adult renal allograft recipients: four cases and a review of the literature.

Authors:  Thomas Fehr; Walter Bossart; Christoph Wahl; Ulrich Binswanger
Journal:  Transplantation       Date:  2002-02-27       Impact factor: 4.939

Review 2.  Extrathymic CD4/CD8 double positive T cells.

Authors:  F A Zuckermann
Journal:  Vet Immunol Immunopathol       Date:  1999-12-15       Impact factor: 2.046

3.  The activation of varicella-zoster virus infections by immunosuppressive therapy.

Authors:  D Rifkind
Journal:  J Lab Clin Med       Date:  1966-09

4.  Varicella-zoster virus-specific cell-mediated immune responses in HIV-infected adults.

Authors:  Nathalie De Castro; Maryvonnick Carmagnat; Solen Kernéis; Catherine Scieux; Claire Rabian; Jean-Michel Molina
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-04       Impact factor: 2.205

5.  Experimental infection of Cynomolgus Macaques (Macaca fascicularis) with human varicella-zoster virus.

Authors:  David O Willer; Aruna P N Ambagala; Richard Pilon; Jacqueline K Chan; Jocelyn Fournier; James Brooks; Paul Sandstrom; Kelly S Macdonald
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

6.  Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency.

Authors:  S Debrus; C Sadzot-Delvaux; A F Nikkels; J Piette; B Rentier
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

7.  Herpes zoster and human immunodeficiency virus infection.

Authors:  S P Buchbinder; M H Katz; N A Hessol; J Y Liu; P M O'Malley; R Underwood; S D Holmberg
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

8.  Robust pro-inflammatory and lesser anti-inflammatory immune responses during primary simian varicella virus infection and reactivation in rhesus macaques.

Authors:  Vicki Traina-Dorge; Robert Sanford; Stephanie James; Lara A Doyle-Meyers; Eileen de Haro; Mary Wellish; Don Gilden; Ravi Mahalingam
Journal:  J Neurovirol       Date:  2014-08-20       Impact factor: 3.739

9.  CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons.

Authors:  T Liu; K M Khanna; X Chen; D J Fink; R L Hendricks
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

10.  Latent herpesvirus infections of neurons in guinea pigs and humans.

Authors:  R B Tenser; R W Hyman
Journal:  Yale J Biol Med       Date:  1987 Mar-Apr
View more
  3 in total

1.  Simian Varicella Virus Pathogenesis in Skin during Varicella and Zoster.

Authors:  Ravi Mahalingam; Brittany Feia; Colin Coleman; Kusala Anupindi; Pratush Saravanan; Amalia Luthens; Amalia Bustillos; Arpita Das; Eileen de Haro; Lara Doyle-Meyers; Jayme Looper; Andrew N Bubak; Christy S Niemeyer; Brent Palmer; Maria A Nagel; Vicki Traina-Dorge
Journal:  Viruses       Date:  2022-05-27       Impact factor: 5.818

2.  Simian Varicella Virus: Molecular Virology and Mechanisms of Pathogenesis.

Authors:  Allen Jankeel; Izabela Coimbra-Ibraim; Ilhem Messaoudi
Journal:  Curr Top Microbiol Immunol       Date:  2021-10-21       Impact factor: 4.737

Review 3.  Current In Vivo Models of Varicella-Zoster Virus Neurotropism.

Authors:  Ravi Mahalingam; Anne Gershon; Michael Gershon; Jeffrey I Cohen; Ann Arvin; Leigh Zerboni; Hua Zhu; Wayne Gray; Ilhem Messaoudi; Vicki Traina-Dorge
Journal:  Viruses       Date:  2019-05-31       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.